.jpg)
Sam User Base Grows 10x in 12 Months
New research presented at EULAR 2026 shows that Steroids and Me (Sam) has grown tenfold since EULAR 2025. With 38,873 users by the end of April 2026, the platform's trajectory reveals the scale of ...
In Conversation With… Peter J. Neumann, ScD
"Nothing in healthcare saves money. It is not quite true, but it is a good adage to keep in mind." Health economics has spent four decades asking whether the trillions spent on US healthcare are ...
Obexelimab Reduces Disease Flares and Steroid-Toxicity in IgG4-RD
An exciting Phase 3 trial has confirmed that obexelimab significantly reduces the risk of disease flare in IgG4-related disease (IgG4-RD) while also delivering measurable reductions in ...
Steroid-Sparing Is Not Enough: GCA Trials Need Toxicity Data
New phase 3 data from the GCAptAIN trial show that secukinumab enabled a shorter steroid taper, less exposure, and meaningfully lower steroid-toxicity in giant cell arteritis (GCA). Although the ...
Secukinumab Delivers Sustained Remission and Toxicity Reduction in PMR
For the majority of patients with polymyalgia rheumatica, glucocorticoids do not provide a durable solution. They induce remission, but they do not maintain it. REPLENISH, the largest PMR clinical ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
